Key Drivers
- Liquidity Cushion
- Persistent Losses
- Cash Burn
AIAI Summary
COGT has shifted from a speculative biotech to a near-term FDA/commercial catalyst story with a strong cash runway, but with much of the upside already anticipated, the stock now depends on clean approval, launch execution, and differentiation more than pipeline headlines.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Persistent Losses
- •Cash Burn
COGT has a very strong liquidity cushion and moderate leverage, but ongoing revenue-free losses and negative free cash flow make its high valuation difficult to justify.
Price Behavior
Key Price Behavior Insights:
- •Broken support
- •Failed rebound
- •Downside stretched
COGT remains in a short-term downtrend after breaking support at $34.0–$34.8 and closing at a new last-month low, with any recovery now needing a quick reclaim of $34.5–$35.0.
Brief rebound from the mid-$35s to $36.98 failed quickly before the slide resumed
Sentiment & News
Key News Insights:
- •Dual Launch Prep
- •Conference Visibility
- •Cash Runway
Cogent Biosciences continues to build momentum with late-stage bezuclastinib and CGT1263 updates, multiple upcoming conference presentations, and a strong cash position that supports development through 2028.
The news flow is supportive for the stock, as advancing clinical data and sufficient funding strengthen the company's execution outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings